Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rasmussen, H. B.
Right arrow Articles by Kassem, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rasmussen, H. B.
Right arrow Articles by Kassem, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (1992) 7: 902-907
© 1992 European Renal Association-European Dialysis and Transplant Association


research-article

Quantification of fetal antigen 2 (FA2) in supernatants of cultured osteoblasts, normal human serum, and serum from patients with chronic renal failure

H. Boje Rasmussen1,, B. Teisner1, F. Bangsgaard-Petersen2, E. Yde-Andersen1 and M. Kassem3

1Institute of Medical Biology, Department of Medical Microbiology, Odense University; Århus AmtsygehusÅrhus, Denmark 2institute of Clinical Research,Department of Nephrology, Odense University Hospital, Odense Århus AmtsygehusÅrhus, Denmark 3University Department of Endocrinology and Metabolism Århus AmtsygehusÅrhus, Denmark

Correspondence and offprint requests to: Correspondence and offprint requests toDr H. Boje Rasmussen, Institute of Medical Biology, Department of Medical Microbiology, Odense University, J. B. Winslows Vej 19, DK-5000 Odense C, Denmark.

Fetal antigen 2 (FA2) was found within the cytoplasm of osteoblasts and in osteoid material, in a bone biopsy with morphological changes of renal osteodystrophy. An ELISA technique for FA2 quantification was developed, and the specificity confirmed by comparison with electroimmunoassay. The intraand interassay coefficient of variations (%) were 8.3 and 9.7 respectively, and the detection limit 0.0004 arbitrary units FA2/1 using second-trimester human amniotic fluid as reference (1 AU FA2/1). FA2 was detected in serum-free supernatants from osteoblast cultures. Following size chromatography, the FA2 distribution (two peaks eluted corresponding to Mw 30 kDa and 100 kDa) in serum from a patient with chronic renal failure complicated with secondary hyperparathyroidism and in human amniotic fluid were identical. Probably due to the detection limit, only one peak fraction (30 kDa) was seen in normal human serum. Significantly greater FA2 concentrations were found in sera (n=14) from patients with chronic renal failure (median: 11.9 mAU FA2/1; range: 5.2–49.0 mAU FA2/1) compared to normal healthy individuals (n=23) (median: 4.1 mAU FA2/1; range 2.4–9.4 mAU FA2/1) (P<0.00001). A close correlation was found between serum FA2 and alkaline phosphatase R(s) = 0.761; P=0.006), c-terminal fraction of PTH (R(s)=0.872; P=0.003) and intact PTH(l-84) (R(s) = 0.904; P=0.011) in the haemodialysis patients.

These data indicate that FA2 is synthesized by osteoblasts and may represent a new marker for metabolic bone changes.

Keywords: fetal antigen 2; osteoblasts; chronic renal failure; ELISA


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Clin. Chem.Home page
J. Brandt, T. N. Krogh, C. H. Jensen, J. K. Frederiksen, and B. Teisner
Thermal Instability of the Trimeric Structure of the N-terminal Propeptide of Human Procollagen Type I in Relation to Assay Technology
Clin. Chem., January 1, 1999; 45(1): 47 - 53.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.